Summary
The rising incidence of inflammatory bowel diseases such as Crohn?s disease (CD) has become a global health care issue in the 21st century. The complex genetic underpinning is increasingly appreciated, while environmental cues and specifically a Western diet are suspected to impact development and course of disease. Mechanistic insights that would support this assumption remain scarce and specific nutrients that trigger a flare are unknown. Westernisation of dietary habits is partly characterised by enrichment of long-chain fatty acids, which fuel metabolic inflammation of tissues beyond the gut. Here, we propose to establish the concept of metabolic gut inflammation as a fuel for CD. By analysing transgenic mice, human CD organoids and two independent CD patient cohorts, we seek to establish how dietary polyunsaturated fatty acids (PUFAs) affect gut inflammation and disease course. The proposed work is based on our previous observations that dietary PUFAs trigger a chemokine response and Crohn?s-like enteritis in mice, which is restricted by intestinal epithelial Glutathione peroxidase 4 (GPX4). GPX4 is an evolutionary conserved anti-oxidative enzyme which shows impaired activity in CD epithelium. The proposed work will identify how dietary PUFAs elicit gut inflammation in mice and which epithelial lineage executes the inflammatory response. In a next step, I propose to establish a critical crosstalk between GPX4 and metabolic hubs in gut epithelium to provide a basis for the concept of metabolic gut inflammation. Finally, we seek to translate findings by establishing that PUFAs evoke an inflammatory response from CD epithelium, and that PUFA intake impacts disease course. MEGI CD comprehends basic and translational science to set the basis for novel therapeutic strategies in a complex illness that requires better treatment modalities. The study will prove the concept of metabolic gut inflammation as a major driver of human CD, a basis for nutritional therapy.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101039320 |
| Start date: | 01-04-2022 |
| End date: | 31-03-2027 |
| Total budget - Public funding: | 1 493 875,00 Euro - 1 493 875,00 Euro |
Cordis data
Original description
The rising incidence of inflammatory bowel diseases such as Crohn?s disease (CD) has become a global health care issue in the 21st century. The complex genetic underpinning is increasingly appreciated, while environmental cues and specifically a Western diet are suspected to impact development and course of disease. Mechanistic insights that would support this assumption remain scarce and specific nutrients that trigger a flare are unknown. Westernisation of dietary habits is partly characterised by enrichment of long-chain fatty acids, which fuel metabolic inflammation of tissues beyond the gut. Here, we propose to establish the concept of metabolic gut inflammation as a fuel for CD. By analysing transgenic mice, human CD organoids and two independent CD patient cohorts, we seek to establish how dietary polyunsaturated fatty acids (PUFAs) affect gut inflammation and disease course. The proposed work is based on our previous observations that dietary PUFAs trigger a chemokine response and Crohn?s-like enteritis in mice, which is restricted by intestinal epithelial Glutathione peroxidase 4 (GPX4). GPX4 is an evolutionary conserved anti-oxidative enzyme which shows impaired activity in CD epithelium. The proposed work will identify how dietary PUFAs elicit gut inflammation in mice and which epithelial lineage executes the inflammatory response. In a next step, I propose to establish a critical crosstalk between GPX4 and metabolic hubs in gut epithelium to provide a basis for the concept of metabolic gut inflammation. Finally, we seek to translate findings by establishing that PUFAs evoke an inflammatory response from CD epithelium, and that PUFA intake impacts disease course. MEGI CD comprehends basic and translational science to set the basis for novel therapeutic strategies in a complex illness that requires better treatment modalities. The study will prove the concept of metabolic gut inflammation as a major driver of human CD, a basis for nutritional therapy.Status
SIGNEDCall topic
ERC-2021-STGUpdate Date
09-02-2023
Images
No images available.
Geographical location(s)
